相关实验视频

Updated: Jul 11, 2025

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

在晚期前列腺癌中,治疗阻力模型和治疗序列

Zachary A Schaaf¹, Shu Ning¹, Amy R Leslie¹

¹Department of Urologic Surgery, University of California Davis, Sacramento, CA 95817, USA.

|November 14, 2023

概括

开发新的抗割前列腺癌 (CRPC) 模型揭示了明显的抗药性模式. 了解这些交叉耐药机制对于在CRPC患者中有效的治疗顺序是关键.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

抗割性前列腺癌 (CRPC) 治疗方法,如下一代抗雄激素疗法 (NGAT),分类剂和PARP抑制剂 (PARPi),面临治疗耐药性.
对于治疗序列如何影响CRPC的交叉耐药性发展的理解有限.
开发获得性抵抗模型对于研究这些机制至关重要.

研究的目的:

开发和表征具有对各种治疗剂获得耐药性的CRPC细胞亚系.
研究不同类型的CRPC药物之间的交叉耐药性模式.
分析与获得的治疗耐药性相关的基因表达变化.

主要方法:

产生CRPC细胞亚系 (C4-2BMDVR,AbiR,ApaR,DaroR,TaxR,2B-olapR),表现出对特定药物的耐药性.
通过对不同处理类别暴露耐药子线来评估交叉电阻配置文件.
RNA测序分析以确定耐药细胞与父细胞中的差异性基因表达模式.

主要成果:

耐NGAT的亚线显示恩扎胺和阿比拉特之间的交叉耐药性,但保留了对税和olaparib的敏感性.
耐多塞尔细胞表现出对cabazitaxel和olaparib的交叉耐药性,同时对NGATs保持敏感.
对olaparib耐药的细胞对其他PARPi具有交叉耐药性,对NGATs和dcetaxel敏感,具有明显的基因表达改变.

结论:

对于CRPC中的不同药物类别,存在不同的耐药性机制.
NGAT耐药性涉及安卓受调节基因的下调,与PARPi或分类基因耐药性不同.
研究结果支持不同药物类别的治疗顺序,但建议在同一类别内谨慎使用.

关键词:

一个是abiraterone.在阿帕胺中.癌症癌症癌症癌症癌症达洛胺胺的使用方法多塞塔克塞尔 (Docetaxel) 是一种药物.酵素胺胺的使用方法这就是Olaparib.前列腺前列腺前列腺电阻的电阻是指电阻的电阻

更多相关视频

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...